Enanta的RSV药物Zelicapavir加快了高危成年人的恢复,尽管没有达到主要目标,但取得了显著成果。 Enanta's RSV drug zelicapavir sped recovery in high-risk adults, showing strong results despite not meeting its main goal.

Enanta制药公司报告说,其实验性口服RSV药物Zelicapavir显著缩短了高危成年人的恢复时间,总症状解析速度为2.2天,心脏病发病者、青蒿素综合症患者或75岁及以上者的恢复时间为6.7天。 Enanta Pharmaceuticals reported that its experimental oral RSV drug zelicapavir significantly shortened recovery time in high-risk adults, with a 2.2-day faster resolution of symptoms overall and a 6.7-day improvement in those with heart failure, COPD, or age 75 and older. 尽管初级终点没有达到,但该药物实现了关键的次级目标,包括更快地改善症状规模、降低住院率和强有力的抗病毒效应,其安全特征与安慰剂相似。 Though the primary endpoint was not met, the drug achieved key secondary goals, including faster symptom scale improvement, reduced hospitalization rates, and strong antiviral effects, with a safety profile similar to placebo. 成果有助于将Zelicapavir推进到第三阶段审判。 The results support advancing zelicapavir to Phase 3 trials.